Delaying Alzheimer Disease Symptoms With Anti-Inflammatory Drugs

This study has been completed.
Information provided by (Responsible Party):
Gary Small, MD, University of California, Los Angeles Identifier:
First received: July 17, 2003
Last updated: February 26, 2013
Last verified: February 2013

July 17, 2003
February 26, 2013
November 2000
November 2005   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT00065169 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Delaying Alzheimer Disease Symptoms With Anti-Inflammatory Drugs
Anti-Inflammation in AD: PET Imaging Supplement

The purpose of this study is to determine whether the anti-inflammatory drug celecoxib can delay the onset of Alzheimer Disease (AD) in people with Age Associated Memory Impairment (AAMI). This study will also evaluate genetic risk and brain structure as potential predictors of mental decline.

AD is one of the most common mental disorders of late life. Preliminary studies indicate that anti-inflammatory drugs may attenuate or prevent AD symptoms, but efficacy trials are needed.

Participants in this study will be randomly assigned to receive either celecoxib or placebo for 18 months. Participants will undergo positron emission tomography (PET) and magnetic resonance imaging (MRI) scans of the brain. Routine laboratory blood tests, cognitive tests, and an electrocardiogram (ECG) will be performed. Participants will also be screened for Parkinson disease. Follow-up testing will be conducted at specific intervals following the study.

Not Provided
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Prevention
  • Alzheimer Disease
  • Dementia
Drug: Celecoxib
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Not Provided
November 2005   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • NIMH diagnostic criteria for Age Associated Memory Impairment (AAMI)
  • Mini-Mental State Examination (MMSE) score between 26 and 30 (unless < 8 years of educational achievement)
  • No significant cerebrovascular disease
  • Estrogen replacement therapy and thyroid replacement therapy (if the participant is euthyroid) are permitted if the therapies are stable for > 1 month
  • Memory and verbal fluency cut-off scores that increase the probability of incipient dementia (Buschke-Fuld: 34; verbal fluency: 46 for letters, 7 for categories; Benton Visual Retention: 5)
  • Adequate visual and auditory acuity to allow neuropsychological testing
  • Normal screening laboratory tests and electrocardiogram (ECG)

Exclusion Criteria:

  • Possible or probable Alzheimer Disease (AD) or other dementia
  • Neurologic or other physical illness that could produce cognitive deterioration
  • History of transient ischemic attacks (TIAs), carotid bruits, or lacunes on an MRI scan
  • History of myocardial infarction within the previous year or unstable cardiac disease
  • Uncontrolled hypertension (systolic BP > 170 or diastolic BP > 100)
  • History of significant liver disease, pulmonary disease, diabetes, or cancer
  • DSM-IV criteria for major psychiatric disorders within the previous 2 years
  • Past or present history of alcoholism or drug dependence
  • Untreated depression as determined by a Hamilton Depression Rating Scale (HAM-D) score of 12 or more
  • Drugs that may significantly affect psychometric test results
  • Centrally active beta-blockers, narcotics, clonidine, anti-Parkinsonian medications, antipsychotics, benzodiazepines, systemic corticosteroids, medications with significant cholinergic or anticholinergic effects, anti-convulsants, warfarin, vitamins other than the standard multivitamin supplement, ginkgo biloba, and any nutraceuticals. Occasional chloral hydrate use will be allowed, but discouraged, for insomnia.
  • Investigational drugs within the previous month or longer, depending on drug half-life
  • Contraindication for MRI scan (e.g., metal in body, claustrophobia)
40 Years to 90 Years
Contact information is only displayed when the study is recruiting subjects
United States
R01 MH58156, R01MH058156, DSIR AT-GP
Not Provided
Gary Small, MD, University of California, Los Angeles
University of California, Los Angeles
National Institute of Mental Health (NIMH)
Not Provided
University of California, Los Angeles
February 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP